Drug intelligence / Profile preview

EAPA115

Development stage: Unknown
Lead developer: HK inno.N Corporation
Modality: Small Molecules
Administration: Oral

Overview

EAPA115 is an investigational drug developed by HK inno.N Corporation. It is currently being evaluated in clinical trials to assess its pharmacodynamics in healthy volunteers. Given its co-administration with Tegoprazan and RAPA115, both of which are likely Potassium-Competitive Acid Blockers (P-CABs) or related compounds, EAPA115 is presumed to be a drug intended to modulate gastric acid secretion. P-CABs work by reversibly inhibiting the H+, K+-ATPase enzyme in gastric parietal cells, thereby reducing acid production.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on EAPA115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EAPA115.

Explore the full profile